Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Rinsho Ketsueki ; 62(1): 30-34, 2021.
Artículo en Japonés | MEDLINE | ID: covidwho-1069962

RESUMEN

From December 2019, a 71-year-old male underwent three cycles of a combination therapy of pomalidomide, bortezomib, and dexamethasone for relapsed multiple myeloma and a very good partial response was achieved. In March 2020, he developed a fever of 38.9°C and computed tomography revealed bilateral ground-glass opacities. Antibiotic therapy was ineffective. Bronchoscopy was performed and bortezomib-induced lung injury was initially suspected. Due to respiratory exacerbation, high-dose steroid therapy was administered, which resulted in a dramatic improvement of the patient's respiratory failure. Thereafter, reverse transcription polymerase chain reaction performed on a preserved bronchial lavage sample tested positive, and thus his diagnosis was corrected to COVID-19 pneumonia. It is difficult to discriminate COVID-19 pneumonia from drug-induced lung disease, as both disorders can present similar ground-glass opacities on computed tomography. Therefore, with this presented case, we summarize our experience with steroid therapy for COVID-19 associated respiratory distress at our institution.


Asunto(s)
Bortezomib/efectos adversos , COVID-19 , Lesión Pulmonar , Insuficiencia Respiratoria , Anciano , Humanos , Lesión Pulmonar/inducido químicamente , Masculino , Insuficiencia Respiratoria/inducido químicamente , Insuficiencia Respiratoria/diagnóstico , SARS-CoV-2 , Esteroides
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA